EyePoint Pharmaceuticals (EYPT) News Today → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free EYPT Stock Alerts $17.63 +0.88 (+5.25%) (As of 05:43 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.9%marketbeat.com - April 29 at 5:31 PMThese Biotechs and IPOs Inspire Big Insider Buying247wallst.com - April 28 at 8:15 AMJennison Associates LLC Takes Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)marketbeat.com - April 25 at 7:27 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 6.6% marketbeat.com - April 24 at 6:15 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up Following Insider Buying Activityamericanbankingnews.com - April 24 at 1:15 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Position Lifted by Federated Hermes Inc.marketbeat.com - April 23 at 5:35 AMInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Buys 581,765 Shares of Stockinsidertrades.com - April 23 at 4:18 AMCormorant Asset Management, Lp Buys 581,765 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stockmarketbeat.com - April 22 at 6:54 PMVeru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare moversmsn.com - April 20 at 9:47 AMBuy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMDmarkets.businessinsider.com - April 19 at 2:14 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading Volumemarketbeat.com - April 18 at 1:56 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 2%marketbeat.com - April 16 at 1:40 PMEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - April 16 at 7:00 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.7%marketbeat.com - April 15 at 2:50 PM35,000 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Purchased by DekaBank Deutsche Girozentralemarketbeat.com - April 15 at 5:16 AMStrong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic Therapiesmarkets.businessinsider.com - April 13 at 8:53 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - April 12 at 2:17 AMEyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialistsglobenewswire.com - April 2 at 7:00 AMEyePoint Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:EYPT)marketbeat.com - March 21 at 11:26 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 4.7% Higher marketbeat.com - March 19 at 3:33 PMEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - March 18 at 7:00 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - March 18 at 2:23 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.2%marketbeat.com - March 13 at 2:16 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $24.40marketbeat.com - March 11 at 11:01 AMScotia Capital Inc. Has $727,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)marketbeat.com - March 10 at 7:23 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%finance.yahoo.com - March 9 at 9:59 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Adage Capital Partners GP L.L.C.marketbeat.com - March 9 at 6:35 AMBuy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Clinical Trials and Market Expansion Potentialmarkets.businessinsider.com - March 8 at 6:58 PMCritical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Knowmarkets.businessinsider.com - March 8 at 6:58 PMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 8 at 1:58 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Issues Quarterly Earnings Resultsmarketbeat.com - March 8 at 11:23 AMEyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 8 at 8:58 AMQ4 2023 EyePoint Pharmaceuticals Inc Earnings Callfinance.yahoo.com - March 8 at 1:13 AMEyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023finance.yahoo.com - March 7 at 3:13 PMEYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 7 at 2:01 PMEyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcriptseekingalpha.com - March 7 at 12:29 PMEyePoint Pharmaceuticals GAAP EPS of -$0.33 beats by $0.16, revenue of $14M beats by $5.3Mmsn.com - March 7 at 10:13 AMEyePoint Pharmaceuticals: Strategic Leadership Appointment and Positive Developments Bolster Buy Ratingmarkets.businessinsider.com - March 7 at 10:13 AMEyePoint Pharmaceuticals: Q4 Earnings Snapshotwashingtonpost.com - March 7 at 10:13 AMEyePoint Pharmaceuticals, Inc. to Post FY2024 Earnings of ($1.83) Per Share, Capital One Financial Forecasts (NASDAQ:EYPT)marketbeat.com - March 7 at 7:37 AMEyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developmentsglobenewswire.com - March 7 at 7:00 AM104,618 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Bought by Trexquant Investment LPmarketbeat.com - March 7 at 5:40 AMEyePoint Pharmaceuticals Q4 2023 Earnings Previewmsn.com - March 6 at 6:52 PMA Preview Of EyePoint Pharmaceuticals's Earningsbenzinga.com - March 6 at 6:52 PMSectoral Asset Management Inc. Sells 135,197 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)marketbeat.com - March 6 at 10:15 AMEyePoint Pharmaceuticals, Inc. to Post FY2028 Earnings of $8.32 Per Share, Capital One Financial Forecasts (NASDAQ:EYPT)marketbeat.com - March 6 at 8:33 AMBuy Rating Affirmed for EyePoint Pharmaceuticals Amid Strategic Leadership Changes and Promising Pipeline Outlookmarkets.businessinsider.com - March 5 at 1:15 AMEyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officerfinanznachrichten.de - March 4 at 10:14 AMEyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officerglobenewswire.com - March 4 at 7:00 AMAcuta Capital Partners LLC Sells 81,872 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)marketbeat.com - March 3 at 12:18 PM Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago. That's why we have released our Free Precious Metals Investment Guide. EYPT Media Mentions By Week EYPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼1.440.34▲Average Medical News Sentiment EYPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼84▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LAB News CTKB News QTRX News PACB News NAUT News HBIO News BNGO News AXDX News OLK News TXG News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
